Tahini and Dermatitis in Breast Cancer
Not Applicable
- Conditions
- Breast Cancer
- Interventions
- Dietary Supplement: tahiniOther: control
- Registration Number
- NCT04890197
- Lead Sponsor
- National Nutrition and Food Technology Institute
- Brief Summary
This study aimed to investigate the effect of tahini on acute radiation dermatitis in breast cancer (BC) patients undergoing radiotherapy (RT).
50 eligible BC patients will randomly assign to consume tahini 48 gr per day during and 1 week after RT or with no intervention (control group). The radiation dermatitis will be assessed weekly according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
- women with Brest Cancer undergoing adjutant Radiation therapy
Exclusion Criteria
- previous history of RT, MRM,
- concomitant presence of two or more malignant tumors
- metastasis to other areas
- allergy or intolerance to tahini
- skin diseases and wounds
- severe liver and renal disease
- autoimmune diseases
- pregnant and lactating women
- those who treated with hypo fraction RT
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description tahini tahini 48 gr per day control control no intervention
- Primary Outcome Measures
Name Time Method severity of dermatitis 4 weeks Change from Baseline severity at 4 weeks. The radiation dermatitis will be assessed according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales
- Secondary Outcome Measures
Name Time Method